Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Immunocore Holdings plc (Nasdaq: IMCR) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company, which specializes in developing transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. PST.

The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website under the 'Investors' tab. A replay of the presentation will be available for a time after the event.

Immunocore to present at the 43^rd Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST).

The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Investor Relations

Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When is Immunocore (IMCR) presenting at the 2025 J.P. Morgan Healthcare Conference?

Immunocore (IMCR) is scheduled to present on Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST) at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch Immunocore's (IMCR) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on Immunocore's website (www.immunocore.com) under the 'Investors' section in 'Events & Presentations'. A replay will be available for a time after the event.

What therapeutic areas does Immunocore (IMCR) focus on?

Immunocore focuses on developing immunomodulating medicines for three main therapeutic areas: cancer, infectious diseases, and autoimmune diseases.

Will there be a replay available of Immunocore's (IMCR) J.P. Morgan presentation?

Yes, a replay of Immunocore's presentation will be made available for a time on the company's website after the event.